Overview

Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients

Status:
Active, not recruiting

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see if the combination of the two cancer drugs, Dacarbazine (DTIC) and a low-dose of Proleukin (IL2), would provide a less toxic and more effective treatment for melanoma than currently available treatments for people with high-risk melanoma. Dacarbazine (DTIC) and Proleukin (IL2) are both FDA-approved drugs for the treatment of melanoma.

Phase:

Phase 2

Details

Lead Sponsor:

James Graham Brown Cancer Center
University of Louisville

Collaborators:

James Graham Brown Cancer Center
University of Louisville

Treatments:

Aldesleukin
Dacarbazine
Interleukin-2